[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 14,075
Citations 0
JAMA Clinical Guidelines Synopsis
January 13, 2020

Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Author Affiliations
  • 1Department of Family Medicine, University of Chicago, Chicago, Illinois
  • 2Northshore University Health System, Glenview, Illinois
  • 3Department of Medicine, Section of General Internal Medicine, University of Chicago Medical Center, Chicago, Illinois
JAMA. Published online January 13, 2020. doi:10.1001/jama.2019.18411

Human papillomavirus is a highly prevalent sexually transmitted infection. Prior to vaccination programs, 1 large study of US female individuals documented an overall HPV prevalence of 26.8%, with the highest prevalence of 44.8% in women aged 20 to 24 years.1 Although many HPV infections are transient and asymptomatic, HPV types 6 and 11 cause about 90% of genital warts. Types 16, 18, 31, 33, 45, 52, and 58 are considered high-risk oncogenic types and are responsible for an estimated 44 000 US cases of cancer each year. HPV causes 90% of US cervical cancers and 70% of US oropharyngeal cancers, and less commonly, anal, vaginal, vulvar, and penile cancer.2